NDT Pharmaceuticals Inc.
NDTP · OTC
12/31/2024 | 12/31/2023 | 12/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $17 | $25 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $17 | $25 | $1 | $2 |
| Operating Income | -$17 | -$25 | -$1 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$54 | $0 | $0 |
| Pre-Tax Income | -$17 | -$79 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$79 | -$1 | -$2 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.001 | -0.004 | -0.006 |
| % Growth | 80% | 87.8% | 35.9% | – |
| EPS Diluted | -0 | -0.001 | -0.004 | -0.006 |
| Weighted Avg Shares Out | 160,004 | 160,004 | 302 | 302 |
| Weighted Avg Shares Out Dil | 160,004 | 160,004 | 302 | 302 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $168 | $0 | $0 |
| EBITDA | -$17 | $89 | -$1 | -$2 |
| % Margin | – | – | – | – |